Cardurion Pharmaceuticals
United States · $560.0M raised
- Business Model
- B2B
- Total Funding
- $560.0M
- Last Round
- $260.0M Series BJan 2023
- Rounds
- 3
About
Clinical-stage biotech developing PDE9 inhibitors for treatment of chronic heart failure.
Summary
Cardurion Pharmaceuticals is a Biotech company based in United States. It has raised $560.0M in total across 3 rounds, most recently a $260.0M Series B round in Jan 2023. Investors include Bain Capital Life Sciences, Polaris Partners and Ascenta Capital.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...